Parma, Italy, November 10, 2026 – [Korewire] – Developed with the University of Parma and tested at Istituto Giannina Gaslini, the patented paediatric supplement earns the Italian company international recognition for its approach to the side-effects of antiepileptic therapy.

For children living with epilepsy, antiepileptic drugs are essential to keep seizures under control, but they often bring side-effects that interfere with school, sleep and mood. It is precisely on this front that Epilamba Junior, the patented paediatric formulation by Italian company Cor.Con. International, has secured a finalist position at the CPHI Pharma Awards 2026, in the Finished Formulation category.

The awards’ shortlist, presented during CPHI Milan at Fiera Milano, celebrated excellence across fifteen core categories of the global pharmaceutical industry. Cor.Con.’s presence among the leading contenders confirms a growing interest in non-pharmacological, supportive solutions that tackle the secondary burdens of chronic therapies. Its scientifically validated food supplement, conceived to reduce the adverse effects of treatment without affecting drug efficacy, has captured the attention of healthcare professionals and industry experts at international level.

Numbers that explain the need

Epilepsy affects more than 70 million people around the world, making it one of the most common neurological conditions. In Europe, about 900,000 children and adolescents have active epilepsy, and roughly 130,000 new paediatric diagnoses are made each year. Standard antiepileptic drugs are fundamental to seizure control, but the trade-offs can be heavy: chronic fatigue, mental fog, mood swings, sleep problems and gastrointestinal disorders are frequent among young patients.

These difficulties spill over into school performance, relationships with peers and psychological health. Physical discomfort and behavioural changes also reduce compliance with treatment, a source of stress for families and doctors alike. While drug research works on ever more refined molecules, everyday clinical practice has been left with an open question: how to manage the side-effects of therapy without adding further pharmacological complexity.

A non-pharmacological strategy rooted in research

Epilamba Junior was created to answer that question. Developed by the company’s scientific team together with the Food and Drug Department of the University of Parma, it offers a structured, non-pharmacological approach. The product does not target seizure frequency; instead, it supports the functional health of the child as a whole, with the aim of improving quality of life during long-term antiepileptic treatment and helping young patients preserve their daily habits, their involvement at school and their emotional stability.

The project followed pharmaceutical-grade research standards, and this is what sets it apart from ordinary supportive supplements. Three physiological parameters were defined from the outset: the formulation must not interfere with the pharmacodynamics of antiepileptic drugs, must not alter their pharmacokinetics and must preserve therapeutic outcomes. This makes it suitable for safe use even alongside complex AED polytherapies. The product combines botanicals with essential nutrients and is protected by an international patent.

What the Gaslini clinical trial showed

Real-world clinical usefulness was assessed through a dedicated clinical trial carried out at the Paediatric Neurology and Muscular Diseases Unit of the Istituto Giannina Gaslini in Genoa. The peer-reviewed findings, recently published in the journal Global Pediatrics, concern paediatric patients on stable antiseizure mono- or polytherapy who were monitored for six months, with attention to both safety and symptom changes.

The results showed that daily supplementation had no effect on seizure frequency or semiology, demonstrating full compatibility with standard medications. Patients also recorded statistically significant improvements in their adverse effect profiles, with clinicians reporting longer attention spans, steadier emotional balance, better sleep quality and lower gastrointestinal discomfort. To encourage consistent long-term use among younger children, the supplement is supplied in easy single-dose sticks with no gluten, no lactose and no added sugars.

Towards a more comprehensive model of care

The recognition received at the CPHI Pharma Awards 2026 reflects how modern medicine is evolving, with the patient’s overall well-being becoming a priority alongside disease control. By creating a first-in-class, patented solution for complications linked to treatment, Cor.Con. International establishes a new category in supportive paediatric neurology.

This step fits within a broader change affecting healthcare pathways globally. Modern therapeutics increasingly recognises that effective care for chronic conditions requires more than suppressing the primary symptoms. In complex paediatric fields, clinical success rests heavily on maintaining the patient’s physical, cognitive and emotional balance for the whole duration of treatment.

As clinical research keeps exploring integrated approaches, the medical community is moving towards a comprehensive model of care, where therapeutic effectiveness and human well-being grow together.

About Cor.Con. International Srl

Cor.Con. International Srl is an Italian healthcare company specializing in innovative nutritional supplements and supportive health solutions. In collaboration with the University of Parma, the company developed Epilamba Junior, a patented paediatric supplement designed to help manage side effects associated with antiepileptic treatments and support children’s overall well-being. Its innovation received international recognition as a finalist at the CPHI Pharma Awards 2026.

Media info,

Contact Person Name: Matteo Callegari

Organization Name: Cor.Con. International Srl

Email: info@corconinternational.com

Website: https://corconinternational.com/

Country Name: Italy

About The Author
KoreWire AP News